TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12452232

Group type: EXPERIMENTAL
Intervention: Intravenous morphine titration in the PACU
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular morphine on demand every 6 hours
Number of subjects: 80
Study: 10632080

Group type: EXPERIMENTAL
Intervention: 400 microg HFA-beclomethasone dipropionate
Number of subjects: 23

Group type: COMPARATOR
Intervention: 400 microg CFC-beclomethasone dipropionate
Number of subjects: 23
Study: 9053973

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms every 6 hours for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin (25 mg three times a day for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for 7 days) + Misoprostol (200 micrograms every 6 hours for 7 days)
Number of subjects: 30
Study: 1791771

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate plus 0.25 mg norgestrel (Cyclabil)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate plus 7.5 mg megestrol acetate (EV + MA)
Number of subjects: 27
Study: 7043657

Group type: EXPERIMENTAL
Intervention: 0.5 mg sulprostone four hourly with laminaria
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.5 mg sulprostone four hourly without laminaria
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1.0 mg sulprostone eight hourly with laminaria
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1.0 mg sulprostone eight hourly without laminaria
Number of subjects: 120
Study: 31807782

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study: 29436397

Group type: EXPERIMENTAL
Intervention: Overdose education combined with a brief behavioural intervention and take-home naloxone
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study: 30772014

Group type: EXPERIMENTAL
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 1021
Study: 28835167

Group type: EXPERIMENTAL
Intervention: Magnetic Anomaly Detection (MAD) by a static pole device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous Wave Detection (CWD) by hand-held metal detector (HHMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic Anomaly Detection (MAD)
Number of subjects: 0
Study: 25989381

Group type: EXPERIMENTAL
Intervention: Silver Cap (medical topical treatment device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care for nipple fissure treatment (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silver Cap
Number of subjects: 40
Study: 23038758

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinorelbine (Regimen B)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Cisplatin, paclitaxel, and gemcitabine (Regimen A)
Number of subjects: 443
Study: 22080794

Group type: EXPERIMENTAL
Intervention: Full prescription coverage
Number of subjects: 5845

Group type: COMPARATOR
Intervention: Usual prescription coverage
Number of subjects: 5845
Study: 20071891

Group type: EXPERIMENTAL
Intervention: cA-QOL (computerized asthma-specific quality-of-life questionnaire)
Number of subjects: 261

Group type: COMPARATOR
Intervention: pA-QOL (paper-and-pencil asthma-specific quality-of-life questionnaire)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: cA-QOL
Number of subjects: 261

Group type: COMPARATOR
Intervention: pA-QOL
Number of subjects: 261
Study: 17014513

Group type: EXPERIMENTAL
Intervention: Surveillance swab cultures (Ssc) with topical therapy based on Ssc results (Group A)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No therapy (Group B)
Number of subjects: 94
Study: 15486370

Group type: COMPARATOR
Intervention: Rollator
Number of subjects: 14
Study: 11728946

Group type: EXPERIMENTAL
Intervention: ACE D allele carriers
Number of subjects: 1454

Group type: COMPARATOR
Intervention: ACE II homozygotes
Number of subjects: 1454
Study: 9226386

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using expanded polytetraflouro‐ethylene (e‐PTFE) membrane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sites (no membrane placed)
Number of subjects: 12
Study: 8216395

Group type: EXPERIMENTAL
Intervention: Auranofin (AUR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination of Auranofin and Methotrexate
Number of subjects: 200
Study: 3624815

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 31185083

Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) - Dental Health Component (DHC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) - Aesthetic Component (AC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Index of Complexity, Outcome, and Need (ICON)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Peer Assessment Rating (PAR) index
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined Index of Orthodontic Treatment Need (CIOTN)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Discrepancy Index (DI)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Facial Aesthetic Index (FAI)
Number of subjects: 101
Study: 28664541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 540
Study: 26645225

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: OCD patients and relatives
Number of subjects: 63
Study: 24292557

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) consisting of 4, 5 min 200 mmHg balloon-cuff inflation/deflations to the upper arm.
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control (placebo).
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC).
Number of subjects: 362
Study: 23643112

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise programme including depression awareness training for care-home staff and 45 min physiotherapist-led group exercise sessions delivered twice weekly.
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise programme for residents depressed at baseline.
Number of subjects: 891
Study: 20626146

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with blood-letting therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine acupuncture only (Control)
Number of subjects: 63
Study: 18975346

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg plus MTX
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg plus MTX
Number of subjects: 982

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 982
Study: 16612487

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum 900 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 14609153

Group type: EXPERIMENTAL
Intervention: IRB‐approved headgear (Canterbury Honeycomb model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified headgear (altered dimensions with increased foam density and thickness)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard model headgear)
Number of subjects: 0
Study: 11022584

Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 212

Group type: COMPARATOR
Intervention: Repeat Pap test
Number of subjects: 212

Group type: COMPARATOR
Intervention: Repeat Pap test showing ASCUS, LSIL or HSIL
Number of subjects: 212
Study: 8863301

Group type: EXPERIMENTAL
Intervention: Real low-level laser treatment (4 x 6 J per treatment, 20 treatments total)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study: 2031770

Group type: EXPERIMENTAL
Intervention: 10 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7.5 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rIFN-alpha therapy (both dosages)
Number of subjects: 24
Study: 392740

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin
Number of subjects: 8
Study: 31358645

Group type: EXPERIMENTAL
Intervention: Cultural integration signaled through shared social norms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27672117

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 25239078

Group type: EXPERIMENTAL
Intervention: IFN-free therapy (danoprevir/r 100/100mg, mericitabine 1000 mg, ribavirin 1000/1200 mg)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Triple therapy (danoprevir/r plus PegIFN alfa-2a/ribavirin)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Quad therapy (danoprevir/r, mericitabine, PegIFN alfa-2a/ribavirin)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IFN-free therapy
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Quad therapy (Quad 24)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Quad therapy (Quad 48)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Quad therapy (partial)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Quad therapy (null 24)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 381
Study: 24057575

Group type: EXPERIMENTAL
Intervention: Currently screened (n = 3,498)
Number of subjects: 5193

Group type: EXPERIMENTAL
Intervention: Overdue (n = 418)
Number of subjects: 5193

Group type: EXPERIMENTAL
Intervention: Never screened (n = 1,277)
Number of subjects: 5193

Group type: COMPARATOR
Intervention: Measurement model validation
Number of subjects: 5193
Study: 21548512

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 240
Study: 20076900

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 32

Group type: COMPARATOR
Intervention: Site-specific repair
Number of subjects: 32
Study: 16409455

Group type: EXPERIMENTAL
Intervention: Second generation COC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Third generation COC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both preparations of COC
Number of subjects: 35
Study: 16129293

Group type: EXPERIMENTAL
Intervention: Removal of lens epithelial cells (LECs) from the anterior capsule during cataract surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no removal of LECs)
Number of subjects: 39
Study: 12504937

Group type: EXPERIMENTAL
Intervention: Lifelong irregular menstrual cycles
Number of subjects: 15253

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 15253

Group type: COMPARATOR
Intervention: Education, age at menarche, oral contraceptive use, smoking habits
Number of subjects: 15253
Study: 9507749

Group type: EXPERIMENTAL
Intervention: Ciprofloxacine 250 mg every 12 hours for 14 days (n = 7)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Trimethoprim 160 mg and sulfamethoxazole 800 mg every 12 hours for 14 days (n = 6)
Number of subjects: 13
Study: 7896975

Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to a distinctive stimulus before each chemotherapy infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2617619

Group type: EXPERIMENTAL
Intervention: Maloprim
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 1049

Group type: COMPARATOR
Intervention: No chemoprophylaxis
Number of subjects: 1049
Study: 346617

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Identical placebos
Number of subjects: 40
Study: 31944827

Group type: EXPERIMENTAL
Intervention: Eclipse™
Number of subjects: 31

Group type: COMPARATOR
Intervention: PSI-Plan
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 31
Study: 29735877

Group type: EXPERIMENTAL
Intervention: Coping skill training program for caregivers delivered in 4-hour sessions over 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Coping skill training program for caregivers
Number of subjects: 34
Study: 28373021

Group type: EXPERIMENTAL
Intervention: Blue soup
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Yellow soup
Number of subjects: 12

Group type: COMPARATOR
Intervention: White soup
Number of subjects: 12
Study: 26048176

Group type: EXPERIMENTAL
Intervention: 3-day intensive mindfulness meditation training
Number of subjects: 35

Group type: COMPARATOR
Intervention: 3-day relaxation training intervention without a mindfulness component
Number of subjects: 35
Study: 23929924

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (losartan or telmisartan)
Number of subjects: 567
Study: 20739446

Group type: EXPERIMENTAL
Intervention: 1-year food and physical activity intervention (14 group sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no group sessions)
Number of subjects: 92
Study: 19099641

Group type: EXPERIMENTAL
Intervention: Haploidentical group (PBSCT combined with BMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HLA matched group (PBSCT regime)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD34+ cell dose > 2 x 10^6/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD34+CD61+ cells infused in haploidentical patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD34+CD61+ cells infused in HLA matched patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD34+ cells infused in total 20 patients
Number of subjects: 24
Study: 15684204

Group type: EXPERIMENTAL
Intervention: Outpatient care with oral levofloxacin therapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Hospitalization with sequential intravenous and oral levofloxacin therapy
Number of subjects: 224
Study: 12850904

Group type: EXPERIMENTAL
Intervention: Fixed diazepam tapering regime
Number of subjects: 44

Group type: COMPARATOR
Intervention: Symptom-triggered taper method (diazepam only in response to withdrawal symptoms)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (Fixed and Symptom-triggered)
Number of subjects: 44
Study: 10229153

Group type: EXPERIMENTAL
Intervention: Combined Low Intensity Laser Therapy/Phototherapy (CLILT) (660-950 nm; 11 J/cm2; pulsed at 73 Hz)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 8896850

Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS2,3)
Number of subjects: 40
Study: 1720843

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7156877

Group type: EXPERIMENTAL
Intervention: Instillation of 0.1 N HCl (2.5, 5, 10, and 15 ml volumes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spontaneous reflux episodes
Number of subjects: 8
Study: 30612797

Group type: EXPERIMENTAL
Intervention: Powdered 0.5% chlorhexidine acetate-based postmilking teat dip (PD)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Foamed 1% iodine-based postmilking teat dip (ID)
Number of subjects: 331
Study: 28419747

Group type: EXPERIMENTAL
Intervention: 75 mg daprodustat
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 500 mg daprodustat
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 26007314

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (20-10-10 mg/kg/d) for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-dose ibuprofen (10-5-5 mg/kg/d) for 3 days
Number of subjects: 60
Study: 23339736

Group type: EXPERIMENTAL
Intervention: Initial maxillary expansion followed by U-bow activator therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal growth effects (Control)
Number of subjects: 66
Study: 23274323

Group type: EXPERIMENTAL
Intervention: Campath 30 mg + methylprednisolone 500 mg followed by TAC monotherapy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ATG 8 mg/kg with TAC + MMF + steroids (Group B)
Number of subjects: 30
Study: 19641203

Group type: EXPERIMENTAL
Intervention: Vaccine group (10 subjects)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 15
Study: 17383777

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 445

Group type: COMPARATOR
Intervention: COPD, heart failure, and falls
Number of subjects: 445

Group type: COMPARATOR
Intervention: All study populations
Number of subjects: 445
Study: 15577470

Group type: EXPERIMENTAL
Intervention: Metasul articulations
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control ceramic‐on‐polyethylene group
Number of subjects: 582
Study: 10668851

Group type: EXPERIMENTAL
Intervention: IL-10 (8 microg/kg)
Number of subjects: 12
Study: 9071476

Group type: EXPERIMENTAL
Intervention: Cyclic estrogen-gestagen replacement therapy (ERT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 91
Study: 8374882

Group type: EXPERIMENTAL
Intervention: 30 minutes of oral cryotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 60 minutes of oral cryotherapy
Number of subjects: 178
Study: 3522529

Group type: EXPERIMENTAL
Intervention: Timentin and tobramycin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Piperacillin and tobramycin
Number of subjects: 151
Study: 31702385

Group type: EXPERIMENTAL
Intervention: Nurse-led individualized self-management program (NISMP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 29144886

Group type: EXPERIMENTAL
Intervention: Proactive care among individuals with chronic lower respiratory disease
Number of subjects: 3307

Group type: COMPARATOR
Intervention: Usual care among individuals with chronic lower respiratory disease
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: Proactive care among individuals without chronic lower respiratory disease
Number of subjects: 3307

Group type: COMPARATOR
Intervention: Usual care among individuals without chronic lower respiratory disease
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: Adjusted analysis for proactive group among individuals with chronic lower respiratory disease
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: Adjusted analysis for proactive group among individuals without chronic lower respiratory disease
Number of subjects: 3307
Study: 27572401

Group type: EXPERIMENTAL
Intervention: Emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: TDF-FTC dosing
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Paired plasma-DBS samples
Number of subjects: 445
Study: 25413828

Group type: EXPERIMENTAL
Intervention: Rhinovirus infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Influenza A infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Adenovirus infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Human coronavirus OC43/229E infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Parainfluenza virus 3 infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Parainfluenza virus 1 infection
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Dual infections
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: ILI occurrence
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: MERS-CoV detection
Number of subjects: 1038
Study: 22333216

Group type: EXPERIMENTAL
Intervention: Cryoablation (n=30, complete ablation)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (n=34, complete ablation)
Number of subjects: 112
Study: 20653637

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing prostitution
Number of subjects: 0
Study: 18724121

Group type: EXPERIMENTAL
Intervention: Upper cervicothoracic sympathetic block (CTGB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no CTGB)
Number of subjects: 28
Study: 15998677

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 18569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18569
Study: 12654665

Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Daptomycin 8 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 10513756

Group type: EXPERIMENTAL
Intervention: Backward stepwise selection with 8 predictors
Number of subjects: 40830

Group type: COMPARATOR
Intervention: No selection applied
Number of subjects: 40830
Study: 8851637

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study: 2228356

Group type: EXPERIMENTAL
Intervention: Flywheel revolution rate on a bicycle wind-loaded simulator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Different FMR machines
Number of subjects: 40
Study: 7378257

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 12
Study: 30775139

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intralesional verapamil
Number of subjects: 15
Study: 30428890

Group type: EXPERIMENTAL
Intervention: Cycling along Downtown route
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cycling along Residential route
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of Downtown vs Residential routes
Number of subjects: 38